Anti-Obesity Prescription Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Anti-Obesity Prescription Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Anti-Obesity Prescription Drugs industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Anti-Obesity Prescription Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Anti-Obesity Prescription Drugs worldwide and market share by regions, with company and product introduction, position in the Anti-Obesity Prescription Drugs market
Market status and development trend of Anti-Obesity Prescription Drugs by types and applications
Cost and profit status of Anti-Obesity Prescription Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Anti-Obesity Prescription Drugs market as:
Global Anti-Obesity Prescription Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Anti-Obesity Prescription Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Global Anti-Obesity Prescription Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Global Anti-Obesity Prescription Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Anti-Obesity Prescription Drugs Sales Volume, Revenue, Price and Gross Margin):
VIVUS
Orexigen Therapeutics
Novo Nordisk
F Hoffmann La Roche
Arena Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Anti-Obesity Prescription Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Anti-Obesity Prescription Drugs industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Anti-Obesity Prescription Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Anti-Obesity Prescription Drugs worldwide and market share by regions, with company and product introduction, position in the Anti-Obesity Prescription Drugs market
Market status and development trend of Anti-Obesity Prescription Drugs by types and applications
Cost and profit status of Anti-Obesity Prescription Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Anti-Obesity Prescription Drugs market as:
Global Anti-Obesity Prescription Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Anti-Obesity Prescription Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Global Anti-Obesity Prescription Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Global Anti-Obesity Prescription Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Anti-Obesity Prescription Drugs Sales Volume, Revenue, Price and Gross Margin):
VIVUS
Orexigen Therapeutics
Novo Nordisk
F Hoffmann La Roche
Arena Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTI-OBESITY PRESCRIPTION DRUGS
1.1 Definition of Anti-Obesity Prescription Drugs in This Report
1.2 Commercial Types of Anti-Obesity Prescription Drugs
1.2.1 Bupropion and Naltrexone
1.2.2 Orlistat
1.2.3 Lorcaserin
1.2.4 Phentermine and Topiramate
1.2.5 Liraglutide
1.3 Downstream Application of Anti-Obesity Prescription Drugs
1.3.1 Hospitals Pharmacies
1.3.2 Retail Pharmacies
1.3.3 E-commerce
1.4 Development History of Anti-Obesity Prescription Drugs
1.5 Market Status and Trend of Anti-Obesity Prescription Drugs 2013-2023
1.5.1 Global Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Anti-Obesity Prescription Drugs 2013-2017
2.2 Sales Market of Anti-Obesity Prescription Drugs by Regions
2.2.1 Sales Volume of Anti-Obesity Prescription Drugs by Regions
2.2.2 Sales Value of Anti-Obesity Prescription Drugs by Regions
2.3 Production Market of Anti-Obesity Prescription Drugs by Regions
2.4 Global Market Forecast of Anti-Obesity Prescription Drugs 2018-2023
2.4.1 Global Market Forecast of Anti-Obesity Prescription Drugs 2018-2023
2.4.2 Market Forecast of Anti-Obesity Prescription Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Anti-Obesity Prescription Drugs by Types
3.2 Sales Value of Anti-Obesity Prescription Drugs by Types
3.3 Market Forecast of Anti-Obesity Prescription Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Anti-Obesity Prescription Drugs by Downstream Industry
4.2 Global Market Forecast of Anti-Obesity Prescription Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Anti-Obesity Prescription Drugs Market Status by Countries
5.1.1 North America Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
5.1.2 North America Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
5.1.3 United States Anti-Obesity Prescription Drugs Market Status (2013-2017)
5.1.4 Canada Anti-Obesity Prescription Drugs Market Status (2013-2017)
5.1.5 Mexico Anti-Obesity Prescription Drugs Market Status (2013-2017)
5.2 North America Anti-Obesity Prescription Drugs Market Status by Manufacturers
5.3 North America Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
5.3.1 North America Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
5.3.2 North America Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
5.4 North America Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Anti-Obesity Prescription Drugs Market Status by Countries
6.1.1 Europe Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
6.1.2 Europe Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.4 UK Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.5 France Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.6 Italy Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.7 Russia Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.8 Spain Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.9 Benelux Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.2 Europe Anti-Obesity Prescription Drugs Market Status by Manufacturers
6.3 Europe Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
6.3.1 Europe Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
6.3.2 Europe Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
6.4 Europe Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Anti-Obesity Prescription Drugs Market Status by Countries
7.1.1 Asia Pacific Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
7.1.3 China Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.1.4 Japan Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.1.5 India Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.1.7 Australia Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.2 Asia Pacific Anti-Obesity Prescription Drugs Market Status by Manufacturers
7.3 Asia Pacific Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Anti-Obesity Prescription Drugs Market Status by Countries
8.1.1 Latin America Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Anti-Obesity Prescription Drugs Market Status (2013-2017)
8.1.4 Argentina Anti-Obesity Prescription Drugs Market Status (2013-2017)
8.1.5 Colombia Anti-Obesity Prescription Drugs Market Status (2013-2017)
8.2 Latin America Anti-Obesity Prescription Drugs Market Status by Manufacturers
8.3 Latin America Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
8.3.2 Latin America Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
8.4 Latin America Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Anti-Obesity Prescription Drugs Market Status by Countries
9.1.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Anti-Obesity Prescription Drugs Market Status (2013-2017)
9.1.4 Africa Anti-Obesity Prescription Drugs Market Status (2013-2017)
9.2 Middle East and Africa Anti-Obesity Prescription Drugs Market Status by Manufacturers
9.3 Middle East and Africa Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Anti-Obesity Prescription Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 ANTI-OBESITY PRESCRIPTION DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Anti-Obesity Prescription Drugs by Major Manufacturers
11.2 Production Value of Anti-Obesity Prescription Drugs by Major Manufacturers
11.3 Basic Information of Anti-Obesity Prescription Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Anti-Obesity Prescription Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Anti-Obesity Prescription Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 ANTI-OBESITY PRESCRIPTION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 VIVUS
12.1.1 Company profile
12.1.2 Representative Anti-Obesity Prescription Drugs Product
12.1.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of VIVUS
12.2 Orexigen Therapeutics
12.2.1 Company profile
12.2.2 Representative Anti-Obesity Prescription Drugs Product
12.2.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
12.3 Novo Nordisk
12.3.1 Company profile
12.3.2 Representative Anti-Obesity Prescription Drugs Product
12.3.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.4 F Hoffmann La Roche
12.4.1 Company profile
12.4.2 Representative Anti-Obesity Prescription Drugs Product
12.4.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of F Hoffmann La Roche
12.5 Arena Pharmaceuticals
12.5.1 Company profile
12.5.2 Representative Anti-Obesity Prescription Drugs Product
12.5.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
13.1 Industry Chain of Anti-Obesity Prescription Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
14.1 Cost Structure Analysis of Anti-Obesity Prescription Drugs
14.2 Raw Materials Cost Analysis of Anti-Obesity Prescription Drugs
14.3 Labor Cost Analysis of Anti-Obesity Prescription Drugs
14.4 Manufacturing Expenses Analysis of Anti-Obesity Prescription Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Anti-Obesity Prescription Drugs in This Report
1.2 Commercial Types of Anti-Obesity Prescription Drugs
1.2.1 Bupropion and Naltrexone
1.2.2 Orlistat
1.2.3 Lorcaserin
1.2.4 Phentermine and Topiramate
1.2.5 Liraglutide
1.3 Downstream Application of Anti-Obesity Prescription Drugs
1.3.1 Hospitals Pharmacies
1.3.2 Retail Pharmacies
1.3.3 E-commerce
1.4 Development History of Anti-Obesity Prescription Drugs
1.5 Market Status and Trend of Anti-Obesity Prescription Drugs 2013-2023
1.5.1 Global Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Anti-Obesity Prescription Drugs 2013-2017
2.2 Sales Market of Anti-Obesity Prescription Drugs by Regions
2.2.1 Sales Volume of Anti-Obesity Prescription Drugs by Regions
2.2.2 Sales Value of Anti-Obesity Prescription Drugs by Regions
2.3 Production Market of Anti-Obesity Prescription Drugs by Regions
2.4 Global Market Forecast of Anti-Obesity Prescription Drugs 2018-2023
2.4.1 Global Market Forecast of Anti-Obesity Prescription Drugs 2018-2023
2.4.2 Market Forecast of Anti-Obesity Prescription Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Anti-Obesity Prescription Drugs by Types
3.2 Sales Value of Anti-Obesity Prescription Drugs by Types
3.3 Market Forecast of Anti-Obesity Prescription Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Anti-Obesity Prescription Drugs by Downstream Industry
4.2 Global Market Forecast of Anti-Obesity Prescription Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Anti-Obesity Prescription Drugs Market Status by Countries
5.1.1 North America Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
5.1.2 North America Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
5.1.3 United States Anti-Obesity Prescription Drugs Market Status (2013-2017)
5.1.4 Canada Anti-Obesity Prescription Drugs Market Status (2013-2017)
5.1.5 Mexico Anti-Obesity Prescription Drugs Market Status (2013-2017)
5.2 North America Anti-Obesity Prescription Drugs Market Status by Manufacturers
5.3 North America Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
5.3.1 North America Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
5.3.2 North America Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
5.4 North America Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Anti-Obesity Prescription Drugs Market Status by Countries
6.1.1 Europe Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
6.1.2 Europe Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.4 UK Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.5 France Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.6 Italy Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.7 Russia Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.8 Spain Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.1.9 Benelux Anti-Obesity Prescription Drugs Market Status (2013-2017)
6.2 Europe Anti-Obesity Prescription Drugs Market Status by Manufacturers
6.3 Europe Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
6.3.1 Europe Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
6.3.2 Europe Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
6.4 Europe Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Anti-Obesity Prescription Drugs Market Status by Countries
7.1.1 Asia Pacific Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
7.1.3 China Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.1.4 Japan Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.1.5 India Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.1.7 Australia Anti-Obesity Prescription Drugs Market Status (2013-2017)
7.2 Asia Pacific Anti-Obesity Prescription Drugs Market Status by Manufacturers
7.3 Asia Pacific Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Anti-Obesity Prescription Drugs Market Status by Countries
8.1.1 Latin America Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Anti-Obesity Prescription Drugs Market Status (2013-2017)
8.1.4 Argentina Anti-Obesity Prescription Drugs Market Status (2013-2017)
8.1.5 Colombia Anti-Obesity Prescription Drugs Market Status (2013-2017)
8.2 Latin America Anti-Obesity Prescription Drugs Market Status by Manufacturers
8.3 Latin America Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
8.3.2 Latin America Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
8.4 Latin America Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Anti-Obesity Prescription Drugs Market Status by Countries
9.1.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Anti-Obesity Prescription Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Anti-Obesity Prescription Drugs Market Status (2013-2017)
9.1.4 Africa Anti-Obesity Prescription Drugs Market Status (2013-2017)
9.2 Middle East and Africa Anti-Obesity Prescription Drugs Market Status by Manufacturers
9.3 Middle East and Africa Anti-Obesity Prescription Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Anti-Obesity Prescription Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Anti-Obesity Prescription Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Anti-Obesity Prescription Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 ANTI-OBESITY PRESCRIPTION DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Anti-Obesity Prescription Drugs by Major Manufacturers
11.2 Production Value of Anti-Obesity Prescription Drugs by Major Manufacturers
11.3 Basic Information of Anti-Obesity Prescription Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Anti-Obesity Prescription Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Anti-Obesity Prescription Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 ANTI-OBESITY PRESCRIPTION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 VIVUS
12.1.1 Company profile
12.1.2 Representative Anti-Obesity Prescription Drugs Product
12.1.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of VIVUS
12.2 Orexigen Therapeutics
12.2.1 Company profile
12.2.2 Representative Anti-Obesity Prescription Drugs Product
12.2.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
12.3 Novo Nordisk
12.3.1 Company profile
12.3.2 Representative Anti-Obesity Prescription Drugs Product
12.3.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.4 F Hoffmann La Roche
12.4.1 Company profile
12.4.2 Representative Anti-Obesity Prescription Drugs Product
12.4.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of F Hoffmann La Roche
12.5 Arena Pharmaceuticals
12.5.1 Company profile
12.5.2 Representative Anti-Obesity Prescription Drugs Product
12.5.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
13.1 Industry Chain of Anti-Obesity Prescription Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
14.1 Cost Structure Analysis of Anti-Obesity Prescription Drugs
14.2 Raw Materials Cost Analysis of Anti-Obesity Prescription Drugs
14.3 Labor Cost Analysis of Anti-Obesity Prescription Drugs
14.4 Manufacturing Expenses Analysis of Anti-Obesity Prescription Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
